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HUMAN PAPILLOMAVIRUS TYPE 16 (HPV16) E6/E7-SPECIFIC CYTO-
TOXIC T LYMPHOCYTES (CTLS) FOR IMMUNOTHERAPY OF HPV-ASSOCI-
ATED MALIGNANCIES
Ramos, C.A.1, Narala, N.1, Leen, A.M.1, Gerdemann, U.1,
Anderson, M.L.2, Sturgis, E.M.3, Savoldo, B.1, Heslop, H.E.1,
Brenner, M.K.1, Rooney, C.M.1 1Baylor College of Medicine, Houston,
TX; 2Baylor College of Medicine, Houston, TX; 3MD Anderson Cancer
Center, Houston, TX
Vaccines prevent HPV-associated cancer (Ca), but their use as
therapy for established Ca has been disappointing. Although the tar-
get tumor cells express the viral E6 and E7 antigens (Ag), patients’
immune responses against virally infected cells are limited, even after
active immunization, likely due to negative environmental cues that
block initial tumor cell recognition and subsequent T cell (TC) ac-
tivation and expansion in vivo. We postulated that ex vivo stimula-
tion of patient TCs in an immunologically favorable milieu would
allow us to reactivate tumor-directed CTLs.
We studied 67 patients withHPV+Ca (16 cervical and 51 oropha-
ryngeal, OPCa). To investigate the presence of HPV16 E6- and E7-
specific TCs (HPV-TCs) in blood, wemeasured the g-IFNELISpot
responses of TCs stimulated by monocyte-derived dendritic cells
(DCs) loaded with pepmixes (peptide libraries of 15-mers overlap-
ping by 11 aa) spanning E6 and E7. Although 75% of OPCa are
HPV16+, we initially found no evidence of E6/E7-reactive T cells
in the patients tested. Because HPV-TCs from these patients may
be anergized by their tumors, we postulated that potent Ag present-
ing strategies might be required for reactivation. In other studies, we
have found that in vitro stimulation of T cells in the presence of DCs
and IL-6, -7, -12 and -15 can induce responses to poorly immuno-
genic Ag. We therefore tested this approach in patients with
HPV+ Ca, and found we could successfully reactivate HPV-TCs
in 8/16 cervical and 32/51 OPCa patients.
Given it is difficult to obtain large numbers of DCs, we expanded
these HPV-TCs to clinically useful numbers by substituting patient
B-cell blasts (BBs) as APCs, which we made by culturing autologous
PBMCs with IL-4 on a CD40L+ feeder layer. Stimulation of DC-
stimulated HPV-TCs by E6/E7 pepmix-loaded BBs further ex-
panded HPV-TC lines (3.8 6 1.5/round), whose phenotype is
summarized in the Table. The epitopes recognized by the HPV-
TCs mapped to E6 aa 49-71, 77-91 and 125-143, and E7 aa 1-19
and 73-87. These cells achieved dose-dependent specific killing of
E6/E7+ target cells (specific lysis up to 45-61% vs. 0-8% in controls,
40:1 E:T ratio). Thus, we have generated true CTLs.
Table. Phenotypic analysis of HPV-specific cell lines
Marker % ± SDCD3 97.5 ± 3.4
CD4 36.7 ± 28.2
CD8 49.4 ± 27.0
CD56 (CD3 negative) 1.5 ± 0.9All cell lines are almost exclusively composed of T cells, with a variable
proportion of CD4+ and CD8+ cells, displaying a predominantly effector
memory phenotype (CD45RA–, CD45RO+, CD62L– and CCR7–). There
are minimal CD3– NK cells. Vb-chain TCR repertoire analysis established
polyclonality.
In summary, we have developed a system that allows the robust
generation of HPV-directed CTLs from the blood of patients with
HPV16+ Ca, and shown that they recognize specific epitopes in tu-
mor-associated Ag. Our lines have the potential to be used for adop-
tive cellular immunotherapy of HPV+ Ca.
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NOVEL THERAPY WITH INTERFERON-a IN COMBINATION WITH DONOR
LYMPHOCYTE INFUSION FOR HIGH RISK ACUTE LEUKEMIA PATIENTS
WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tang, X., Zhou, Q., Jin, Z., Fu, Z., Ye, C., Shi, X., Sun, A., Wu, D. The
First Affiliated Hospital of SoochowUniversity, Jiangsu Institute of Hema-
tology, Suzhou, Jiangsu Province, China
Objective: In order to improve the graft versus leukemia (GVL) ef-
fect of DLI, we investigated the efficacy and safety of combininginterferon-a with DLI (aDLI) in patients with high risk acute leuke-
mia (AL) who relapsed after allo-HSCT, and compared the efficacy,
toxicity and leukemia free survival (LFS) of aDLI and traditional do-
nor lymphocyte infusion (tDLI) in our transplantation center.
Methods: Sixteen acute leukemia patients were treated with inter-
feron-a-2b therapy at a dose of 3106U/day subcutaneously for 5
days followed by G-CSF mobilized donor peripheral stem cell infu-
sion. (termed with ‘‘aDLI’’). The median duration of IFN-a treat-
ment was 17 (5-50) days, and the median CD3+ cells dose was
9.25107/kg (4-20107/kg). In parallel, we retrospectively analyzed
the results of tDLI for 14 AL patients with hematologic relapse post
allo-HSCT treated in the same period in our center, and compared
the efficacy, toxicity and LFS of tDLI with aDLI.
Results: Patients treated on the aDLI protocol included 9 ALL and
7 AML, with a median age of 26.5 years. Fourteen of 16 patients had
high risk AL. The median relapse time was 5.5 (range, 1-25) months
post transplant. Salvage chemotherapy was administrated in 7 pa-
tients before aDLI, with only 3 patients achieved CR. The overall
CR rate for aDLI protocol was 75% (12/16), with CR rate of
aDLI alone at 66.7% (6/9). The median time from aDLI to bone
marrow CR was 7 (6-14) days, and the median time to molecular
CR (MCR) and full donor chemerism (median level was 96.3%) in
responsive patients were 2 weeks post DLI. With a median follow-
up of 5.5 (range, 1-34) months, 7 patients were alive with durable
molecular CR. Two-year LFSwas 50%.Treatment related toxicities
included episode of fever, GVHD and myelosuppression. The tDLI
group had similar demographic characteristics with disease subtypes,
transplant and relapse history. Compared to tDLI, the aDLI proto-
col had higher CR rate (75.0% vs 14.3%, p5 0.001), faster response
(median time to obtain BMCRwere 7 days), and significant better 2-
year LFS (50.0% vs 7.1%, p 5 0.05). Importantly, there was no
significant difference between the two groups with respect to the in-
cidence of pancytopenia (53.8% vs 75%, p.0.05) and treatment re-
lated mortality (18.8% vs 7.1%, p.0.05).
Conclusion: IFN-a-2b in combination with DLI appears to induce
rapid anddurable remissions inhigh risk acute leukemiapatientswho re-
lapsed following allo-HSCT, with acceptable treatment-related toxicity.
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SALVAGE T CELL THERAPY FOR THERAPY RESISTANT VIRAL DISEASES
AFTER STEM CELL TRANSPLANTATION
Uhlin, M.1,2, Gertow, J.2, Okas, M.2, Uzunel, M.2, Remberger, M.1,
Mattsson, J.1,2 1Karolinska University Hospital, Stockholm, Sweden;
2Karolinska Institute, Stockholm, Sweden
Epstein-Barr virus (EBV), cytomegalovirus (CMV) and adenoviral
reactivations are frequent complications after allogeneic SCT be-
cause of a lack of T cell control due to extensive immunosuppression.
Cytotoxic T lymphocytes (CTLs) that recognize viral antigens are
themost important immune effector mechanism controlling the per-
sistent viral infections.
First-line treatment for viral reactivation is dose reduction of the im-
munosuppressive drugs and/or anti-viral therapy. For PTLD this is
followed by rituximab (anti-CD20 monoclonal antibody). Despite
these multiple treatment strategies, the l mortality from drug-resistant
viremia after SCT is still considerable. Another treatment approach is
adoptive transfer of virus specific CTLs from the donor. The standard
method of adoptive T cell immunotherapy is laborious and time-con-
suming and is often too late to be administrated to the patient.
We have developed a clinical separation protocol for virus specific
CTLs based on labeling with multimeric complexes containing re-
combinant HLA molecules together with virus derived peptides. By
combining this labeling technique with a secondary magnetic sorting
wehavemanaged toget a high purity of specificCTLs.This high purity
diminish the risk of creatingGVHDin the recipient even if the adoptive
transfer of cells is done in an allogeneic or haplo-identical setting.
We first used this protocol in an 18 year old patient with life-
threatening PTLD. The patient developed an EBV associated lym-
phoma involving lungs, liver and both kidneys and also showed
extremely high EBV titers in blood. It was decided to give her
EBV specific CTLs from her mother. 2 months after the given
EBV specific CTL infusion the EBV associated lymphoma was in
complete regression. After this we have further successfully treated
seven patients with life threatening viral disease (Adeno, CMV and
EBV) with good efficacy.We could see a clinical and immunological
Oral Presentations S221response in six out of eigth patients. In five out of six of these re-
sponding patients we have been able to identify infused T cells using
chimerism analysis and SNP markers specific for the CTL donor.
This method opens up the possibility to rapidly treat patients which
are in acute need of T cell therapy and cannot wait for prolonged ex-
pansion techniques or cannot tolerate standard treatment regiment.
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EXPRESSION OF a4b7 INTEGRIN ON MEMORY CD8+ T-CELLS IS IN-
CREASED IN PATIENTS AT PRESENTATION OF ACUTE INTESTINAL
GRAFT-VS-HOST DISEASE
Chen, Y.-B.1, McDonough, S.2, Chen, H.3, Kennedy, J.1, Ballen, K.K.1,
Dey, B.R.1, McAfee, S.L.1, Spitzer, T.R.1, Jagasia, M.3, Ritz, J.2 1Mas-
sachusetts General Hospital, Boston, MA; 2Dana-Farber Cancer Institute,
Boston, MA; 3Vanderbilt University, Nashville, TN
Background: Acute intestinal graft-vs.-host disease (GVHD) re-
mains a major source of morbidity and mortality after allogeneic he-
matopoietic cell transplantation (HCT). a4b7 integrin is a cell
surface molecule thought to mediate specific lymphocyte trafficking
to intestinal tissue.Our previous work suggested that upregulation of
a4b7 integrin expression on memory CD4+ and CD8+ peripheral
blood T-cells after HCT correlated with the future development
of intestinal GVHD.
Methods: In this analysis, peripheral blood mononuclear cells were
collected from patients at the time of presentation of symptoms of
GVHD prior to the initiation of systemic corticosteroids. In total,
27 patient samples were collected prospectively after HCT, which
were then retrospectively divided into 3 cohorts: GUT (intestinal
GVHD, n 5 11), SKIN (cutaneous GVHD, n 5 9), and NONE
(suggestive symptoms but negative evaluation for GVHD, n 5 7).
Sample collection ranged from day +23 to day +194 after HCT
and was based on symptoms or signs suggestive of GVHD. One pa-
tient developed GVHD after donor leukocyte infusion (DLI).
Results: There were no significant differences in baseline characteris-
tics between the groups. Analysis by flow cytometry showed that GUT
patients had a significantly higher percentage of a4b7 integrin express-
ing memory (defined by CD45RO+) peripheral blood CD8+ T-cells
(median 7.7%, range 0.5%-28.1%) compared to the SKIN group
(2.1%, 0%-3.1%, p 5 0.03), the NONE group (1%, 0.2%-2.2%, p
5 0.02), or the SKIN and NONE groups combined into one NON-
GUT (n5 16) group (1.6%, 0%-3.1%, p5 0.01). Time of sample col-
lection after HCT had no effect on the expression of a4b7 integrin.
Conclusion: These results add to the evidence that upregulation of
a4b7 integrin on memory CD8+ T-cells may be involved in lympho-
cyte trafficking in acute intestinal GVHD and increased expression
may be a potential biomarker. More importantly, a4b7 integrin may
represent a novel target of treatment and prophylaxis of acute intestinal
GVHD after HCTwith specific monoclonal antibodies already in de-
velopment for the treatment of inflammatory bowel disease. Analysis
with a larger number of samples is planned to confirm these results.
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INFUSION OF SYNGENEIC APOPTOTIC CELLS PRIOR TO BONE MARROW
TRANSPLANTATION DECREASES TCELL PROLIFERATION AND IN-
CREASES SURVIVAL
Florek, M., Sega, E.I., Mueller, A.M.S., Leveson-Gower, D.B.,
Shizuru, J.A., Negrin, R.S. Stanford University, Stanford, CA
To prevent graft versus host disease (GVHD) the graft has to be
rendered tolerant to avoid alloreactivity towards the host. One
promising approach to induce tolerance is to administer apoptotic
cells to the host. Apoptosis can be induced by extracorporeal photo-
pheresis (ECP), a therapy based on exposure of cells to photoactiv-
able 8-methoxypsoralen (8MPO) and UVA irradiation. The effect
of ECP treatment is at least in part, due to alteration of dendritic
cell (DC) maturation, leading to reduced Tcell activation. In con-
trast to clinical practice where ECP is only applied to established
GVHD, we have developed a pre-emptive murine model with the
aim of inhibiting the initiation phase of acute GVHD.
Methods: Host apoptotic splenocytes were infused into MHC
matched or mismatched recipients 5 or 2 days prior to lethal irradi-ation and BMT. Apoptotis of cells was generated by 8-MPO and
UVA light (UVAR light set, Therakos). Mice were followed for
GVHD score and survival.
Results: ECP-treated mice survived longer both across major (me-
dian survival 51 versus 26 days, p\0.0001) and minor (median sur-
vival 56.5 versus 9 days, p\0.002) MHC barriers. Importantly,
even though ECP treatment promoted tolerance against the host it
did not impact the graft versus tumor effect in a B-cell lymphoma
model. In vivo experiments using bioluminescent imaging showed
reduced CD4+Tcell proliferation during the initiation phase of
GVHD (day+4) in ECP-treated mice compared to mice receiving
Tcon only. The same result was found in CFSE labeled Tcells re-
isolated on day+4. FACS-sorted DC incubated with apoptotic cells
for 2 days in vitro showed a diminished capability to induce Tcell
proliferation. Re-isolation experiments on day+3 confirmed lower
expression of homing (P-Selectin, a4b7) and activation (CD44,
CD69) markers on donor Tcells in ECP treated groups, indicating
slower trafficking to GvHD target organs. Furthermore, at day+7
ECP-treated groups showed increased FoxP3-expressing host Tregs
in comparison to control groups whereas donor Treg were similar in
both groups.
In summary, ECP treatment prior to transplantation led to a sig-
nificant survival benefit with no impact on graft versus tumor effect;
reduced CD4+ Tcell proliferation; delayed expression of homing
and activation markers during the initiation phase of GVHD and
an increase in host Treg. Overall our work suggests that pre-emptive
ECP of host cells prior to BMT may be a clinically relevant strategy
to prevent acute GVHD.51
LOW LEVELS OF 25-HYDROXYVITAMIN D PRIOR TO ALLOGENEIC
TRANSPLANTATION CORRELATEWITH THE DEVELOPMENT OF CHRONIC
GRAFT-VERSUS-HOST DISEASE
Glotzbecker, B.E.1, Ho, V.T.1, Aldridge, J.1, Kim, H.T.1, Horowitz, G.2,
Ritz, J.1, Soiffer, R.J.1, Avigan, D.2, Rosenblatt, J.2 1Dana Farber Cancer
Institute, Boston,MA; 2Beth Israel Deaconess Medical Center, Boston,MA
Graft-versus-host disease (GVHD) remains a significant cause
of morbidity and mortality following allogeneic hematopoietic
stem cell transplantation. GVHD is mediated by the activation
and expansion of donor derived alloreactive lymphocytes stimu-
lated in part by residual host dendritic cells (DCs) and donor
DCs with cross presentation of alloantigens. Vitamin D is a hor-
mone essential for calcium homeostasis and exhibits potent immu-
nomodulatory characteristics. We have demonstrated that vitamin
D exposure inhibits DC maturation and DC mediated stimulation
of allogeneic T cells. As such, we hypothesized that vitamin D de-
ficiency may result in the enhanced capacity of DCs to induce
GVHD. In this study, we performed a retrospective case-control
study to evaluate whether monohydroxyvitamin D levels measured
in serum samples obtained from patients prior to allogeneic trans-
plantation were predictive of the risk for GVHD. Fifty-three pa-
tients aged 18-60 who underwent a myeloablative matched related
or matched unrelated donor transplant between December 2000
and December 2009 were included in the analysis. 25-OH vitamin
D concentrations were measured by an ELISA assay prior to
transplantation. The median 25-OH vitamin D level was 21.9
ng/mL (range 7.8-45.7). Patients were divided into two cohorts
based on a vitamin D level: \ 25 ng/mL (32 patients) or $25
ng/mL (21 patients). Remarkably, the cumulative incidence (CI)
of chronic GVHD (cGVHD) at 2 years in patients with 25-OH
vitamin D \25 was 63.8%, compared to 23.8% in patients with
vitamin D levels $ 25 (p 5 0.009). Similarly the 2 year CI of ex-
tensive cGVHD was significantly greater in patients with vitamin
D levels\25 compared to those with $25 (54.5% versus 14.3%,
p 5 0.005). This result is consistent in multivariable competing
risks model for which patient and transplant related factors men-
tioned above were adjusted (HR 5.26, p 5 0.02). Three-year pro-
gression-free survival and overall survival were similar between the
two groups (51% vs. 47%, p 5 0.61; and 53% vs. 50%, p 5 0.57
respectively). In summary, vitamin D deficiency prior to allogeneic
transplantation is associated with a significantly increased risk of
chronic GVHD. A prospective clinical trial evaluating the use of
vitamin D for the prevention of chronic GVHD is planned.
